Aspirin Alone Holds Up After Left Atrial Appendage Closure in JAMA Trial
In patients with atrial fibrillation who underwent successful left atrial appendage closure, aspirin alone matched more intensive antithrombotic approaches through six months. The trial adds weight to a simpler post-procedure strategy for carefully selected patients after implantation of Boston Scientific’s Watchman FLX Pro device.
The main comparison centered on a composite of death, stroke, systemic embolism, or major bleeding. Rates came in at 3.3% with aspirin alone, 5.1% with a reduced-dose non-vitamin K oral anticoagulant for three months followed by aspirin, and 6.9% with dual antiplatelet therapy. Those numbers place aspirin alone on solid footing in the early post-closure period, at least in uncomplicated implants and within the trial’s six-month window.
Why the Post-Implant Antithrombotic Choice Matters
Left atrial appendage closure is intended to lower cardioembolic risk in atrial fibrillation by sealing the appendage where thrombus often forms. The price of that mechanical protection is a short period of device-related thrombosis risk while the implant endothelializes. Antithrombotic therapy during that interval has to balance two competing dangers: clot formation on or around the device, and bleeding from the drugs used to prevent it.
This is where the study’s result carries real bedside relevance. A simpler regimen can reduce medication burden, limit exposure to bleeding risk, and ease adherence after a procedure already meant to spare patients from long-term anticoagulation. For clinicians choosing among post-implant strategies, the finding supports a narrower approach when the implant is uncomplicated and the patient profile fits the trial population.
The trial randomized 1,857 patients after implantation of the Watchman FLX Pro device. That is a substantial cohort for a device-adjacent anticoagulation question, and it gives the results enough scale to matter in daily practice. Still, the interpretation stays tied to the study design: the comparison did not involve full-dose anticoagulation, and the follow-up ended at six months.
The Composite Endpoint Favored Simplicity Without Early Penalty
The most clinically important feature of the study is not simply that aspirin alone performed well, but that it did so without an obvious early tradeoff in ischemic protection. In atrial fibrillation care, clinicians are used to thinking in terms of layered antithrombotic intensity, but device closure changes the equation. Once the appendage is excluded from circulation, the residual thrombotic burden shifts away from the original substrate that drove the indication for chronic anticoagulation.
The lower composite event rate with aspirin alone fits that biology. After a successful implant, the main therapeutic goal becomes preventing surface thrombus on a healing device rather than suppressing the ongoing embolic risk of an open appendage. A less intensive regimen can be enough when the mechanical solution is functioning as intended and the implant course is uncomplicated.
One practical consequence is immediate: fewer patients may need to carry the bleeding liability of dual antiplatelet therapy or short-term anticoagulation if they are otherwise good candidates for closure and recovery. In a population already selected for a structural alternative to indefinite anticoagulation, that difference can shape discharge planning, follow-up, and patient counseling.
Trial Boundaries Keep the Result Focused
Boston Scientific sponsored the study, and five authors were company employees. Industry sponsorship does not invalidate the data, but it does make the device-specific context impossible to ignore. The device used was the Watchman FLX Pro, so the results should not be casually stretched to every appendage-closure platform or every post-procedural regimen in current use.
The trial also leaves several important questions unanswered. It included only uncomplicated implants, so the results do not speak to more difficult procedures, incomplete seals, peri-device leaks, or other procedural complications that may alter thrombosis risk. The six-month horizon is another meaningful limit, because late events, longer-term bleeding tradeoffs, and extended endothelialization patterns were not part of the comparison.
Most importantly, the study did not compare aspirin alone or the reduced-dose anticoagulant strategy with full-dose anticoagulation. That omission matters for clinicians who are still deciding how much antithrombotic protection is enough in a patient whose stroke and bleeding risks do not fit neatly into a single category. A mechanical solution lowers risk, but it does not erase uncertainty about how aggressively to treat every patient immediately after implantation.
What the Result Means at the Bedside
For electrophysiologists and structural heart teams, the study strengthens a pragmatic argument for de-escalation after successful appendage closure. Patients who receive the Watchman FLX Pro and recover without procedural complications may not need layered antithrombotic therapy to reach acceptable short-term outcomes. That can simplify care in older patients, in those with prior bleeding concerns, and in anyone for whom medication burden itself is a barrier.
The study also reinforces a broader principle in atrial fibrillation management: when a mechanical strategy replaces the need for indefinite systemic anticoagulation, post-procedure therapy should be judged by the specific healing phase rather than by habit. The biologic target is no longer the atrial substrate alone; it is the healing device surface, where thrombosis risk is temporary and time-limited.
Even so, the result should stay anchored to the exact population studied. Uncomplicated implants, one device system, and six months of follow-up form a useful but narrow evidence base. Longer observation and comparisons with more intensive anticoagulation strategies will determine whether aspirin alone remains sufficient once the early post-implant period gives way to longer-term care.